Compare LXU & SLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LXU | SLS |
|---|---|---|
| Founded | 1968 | 2012 |
| Country | United States | United States |
| Employees | 513 | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 781.3M | 924.5M |
| IPO Year | 2006 | 2007 |
| Metric | LXU | SLS |
|---|---|---|
| Price | $10.96 | $12.86 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | ★ $14.63 | $10.00 |
| AVG Volume (30 Days) | 756.7K | ★ 10.9M |
| Earning Date | 04-29-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 225.93 | 50.00 |
| EPS | ★ 0.27 | N/A |
| Revenue | ★ $615,208,000.00 | N/A |
| Revenue This Year | $13.69 | N/A |
| Revenue Next Year | N/A | $110.98 |
| P/E Ratio | $40.41 | ★ N/A |
| Revenue Growth | ★ 17.77 | N/A |
| 52 Week Low | $7.09 | $1.39 |
| 52 Week High | $17.22 | $15.88 |
| Indicator | LXU | SLS |
|---|---|---|
| Relative Strength Index (RSI) | 40.02 | 59.89 |
| Support Level | $10.53 | $3.91 |
| Resistance Level | $15.56 | $15.88 |
| Average True Range (ATR) | 0.37 | 1.66 |
| MACD | 0.10 | 0.06 |
| Stochastic Oscillator | 48.02 | 60.23 |
LSB Industries Inc is engaged in the manufacturing and sale of chemical products in the United States. The company manufactures and sells chemical products for the agricultural and industrial sectors. Its products include ammonia, fertilizer grade ammonium nitrate (AN and HDAN), and urea ammonia nitrate (UAN) for agricultural applications; high purity and commercial grade ammonia, sulfuric acids, concentrated, blended, and regular nitric acid, mixed nitrating acids, carbon dioxide, and diesel exhaust fluid for industrial applications; and industrial grade AN (LDAN) and AN solutions for mining applications. Its products are sold through distributors and directly to end customers throughout the United States and other parts of North America.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.